Alvocidib
- Generic Name
- Alvocidib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20ClNO5
- CAS Number
- 146426-40-6
- Unique Ingredient Identifier
- 45AD6X575G
- Background
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
- Indication
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Kolkata scientists identify therapy to help cancer patients overcome resistance to current treatments
Scientists at IACS, Kolkata, identified TDP1 as a DNA repair enzyme crucial for cancer cell survival during Top1 inhibitor chemotherapy. CDK1 phosphorylates TDP1, enhancing its repair function. Targeting both CDK1 and TDP1 with inhibitors could improve treatment effectiveness and overcome drug resistance.
Breakthrough therapy by Indian scientists offers hope for patients resistant to current cancer treatments
Scientists at IACS, Kolkata, developed a novel cancer therapy targeting TDP1, a DNA repair enzyme, suggesting a combination therapy with CDK1 inhibitors to overcome drug resistance and enhance treatment effectiveness.
New cancer therapy target could help patients overcome resistant to current treatments
Scientists identified TDP1 as a DNA repair enzyme crucial for cancer cell survival, suggesting CDK1 inhibitors alongside Top1 inhibitors could enhance cancer treatment, especially for resistant cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath